Literature DB >> 30478963

Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study.

Emmanuel Dudoignon1, Alexandre Alanio2,3,4, James Anstey5, François Depret1,3, Maxime Coutrot1,3, Alexandre Fratani1, Marion Jully1, Alexandru Cupaciu1, Maïté Chaussard1, Haikel Oueslati1, Axelle Ferry1, Mourad Benyamina1, Christian de Tymowski1, David Boccara6, Kevin Serror6, Marc Chaouat6, Maurice Mimoun6, Matthieu Lafaurie7, Blandine Denis7, Maud Gits-Muselli2,3,4, Stephane Bretagne2,3,4, Alexandre Mebazaa1,3,8, Matthieu Legrand1,3,8, Sabri Soussi1.   

Abstract

BACKGROUND: Patients with extensive burns are at risk of developing candidemia.
OBJECTIVES: To identify potentially modifiable risk factors and outcomes of candidemia in critically ill burns patients. PATIENTS AND METHODS: Retrospective matched cohort study including adult burns patients. Patients who developed candidemia were matched with burns patients with Candida spp colonisation and sepsis or septic shock without candidemia in a ratio of 1:3 (same severity scores and colonisation index). Univariate and multiple regression analyses were performed.
RESULTS: Of 130 severely burned patients with Candida spp colonisation and at least one episode of sepsis or septic shock, 14 were diagnosed with candidemia. In the candidemia group, patients had a median (IQR) total burns surface area (TBSA) of 57 (38-68)%, SAPSII of 43 (36-58) and ABSI of 11 (8-13). Multiple regression analysis showed that only duration of prior antibiotic therapy was independently associated with candidemia. ICU mortality was higher in the candidemia group (71% vs 35% [P = 0.02]). The log-rank test for 28-day mortality comparing patients with candidemia treated with an empirical strategy vs a curative strategy did not reach significance (P = 0.056).
CONCLUSIONS: Burns patients having received recent antibiotherapy have a higher risk of candidemia. Antifungal strategies did not influence outcome in this series.
© 2018 Blackwell Verlag GmbH.

Entities:  

Keywords:  antifungals; burns; candidemia; critically ill; outcome; risk factors

Mesh:

Substances:

Year:  2018        PMID: 30478963     DOI: 10.1111/myc.12872

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  5 in total

1.  Clinical and Microbiological Characteristics of Neonates with Candidemia and Impacts of Therapeutic Strategies on the Outcomes.

Authors:  Yu-Ning Chen; Jen-Fu Hsu; Shih-Ming Chu; Mei-Yin Lai; Chih Lin; Hsuan-Rong Huang; Peng-Hong Yang; Ming-Chou Chiang; Ming-Horng Tsai
Journal:  J Fungi (Basel)       Date:  2022-04-29

2.  Oral Health Knowledge Level of Nursing Staff Working in Semi-Intensive Heart Failure Units.

Authors:  Stefano Cianetti; Paola Anderini; Stefano Pagano; Paolo Eusebi; Massimiliano Orso; Rosario Salvato; Guido Lombardo
Journal:  J Multidiscip Healthc       Date:  2020-02-12

3.  The A2B trial, antibiotic prophylaxis for excision-graft surgery in burn patients: a multicenter randomized double-blind study.

Authors:  François Dépret; Boris Farny; Mathieu Jeanne; Kada Klouche; Thomas Leclerc; Karine Nouette-Gaulain; Olivier Pantet; Francis Rémerand; Antoine Roquilly; Anne-Françoise Rousseau; Simon Sztajnic; Sandrine Wiramus; Eric Vicaut; Matthieu Legrand
Journal:  Trials       Date:  2020-11-25       Impact factor: 2.279

4.  Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.

Authors:  Matteo Bassetti; Antonio Vena; Daniele R Giacobbe; Cecilia Trucchi; Filippo Ansaldi; Massimo Antonelli; Vaclava Adamkova; Cristiano Alicino; Maria-Panagiota Almyroudi; Enora Atchade; Anna M Azzini; Pierluigi Brugnaro; Novella Carannante; Maddalena Peghin; Marco Berruti; Alessia Carnelutti; Nadia Castaldo; Silvia Corcione; Andrea Cortegiani; George Dimopoulos; Simon Dubler; José L García-Garmendia; Massimo Girardis; Oliver A Cornely; Stefano Ianniruberto; Bart Jan Kullberg; Katrien Lagrou; Clement Lebihan; Roberto Luzzati; Manu Malbrain; Maria Merelli; Ana J Marques; Ignacio Martin-Loeches; Alessio Mesini; José-Artur Paiva; Santi Maurizio Raineri; Riina Rautemaa-Richardson; Jeroen Schouten; Herbert Spapen; Polychronis Tasioudis; Jean-François Timsit; Valentino Tisa; Mario Tumbarello; Charlotte H S B Van den Berg; Benoit Veber; Mario Venditti; Guillaume Voiriot; Joost Wauters; Nathalie Zappella; Philippe Montravers
Journal:  Infect Dis Ther       Date:  2022-02-19

5.  β-Lapachone enhances the antifungal activity of fluconazole against a Pdr5p-mediated resistant Saccharomyces cerevisiae strain.

Authors:  Daniel Clemente de Moraes; Karina Martins Cardoso; Levy Tenório Sousa Domingos; Maria do Carmo Freire Ribeiro Pinto; Robson Q Monteiro; Antônio Ferreira-Pereira
Journal:  Braz J Microbiol       Date:  2020-03-10       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.